Physician profile
Kendrick Wang
NPI 1265977912
$9,224.82
in general payments reported to CMS, 2019-2025
14 companies · $4,042 in 2025
The $4,042 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $496 · 2024: $4,687 · 2025: $4,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,801 · Travel and Lodging: $2,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,801.34 |
| Travel and Lodging | $2,423.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,683.96 | 2024-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idosetr, Idose |
| Abbvie INC. | $2,066.21 | 2024-2025 | |
| Alcon Vision LLC | $1,285.68 | 2023-2025 | Clareon Panoptix Pro, Clareon, Unity |
| Sight Sciences, INC. | $842.50 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument, Tearcare System |
| Tarsus Pharmaceuticals, INC. | $495.12 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $463.06 | 2024-2025 | Tecnis Simplicity, Veritas Vision System, Tecnis Iol |
| New World Medical,INC. | $430.80 | 2024-2025 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Bausch & Lomb Americas INC. | $301.76 | 2025 | Envista Mx60 Iol, Envista Envy Iol, Vyzulta |
| Genentech USA, INC. | $293.86 | 2023-2024 | Vabysmo |
| Rxsight INC | $135.17 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Carl Zeiss Meditec USA, INC. | $130.84 | 2024 | Atlas 500, Quatera 700, Mel 90 |
| Sun Pharmaceutical Industries INC. | $44.13 | 2025 | |
| Dompe US, INC. | $30.97 | 2025 | Oxervate |
| Harrow Eye, LLC | $20.76 | 2025 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendrick Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.